BeyondSpring Inc. (BYSI)

Overview

BeyondSpring Inc., established in 2010 and based in New York, New York, operates as a clinical stage biopharmaceutical enterprise focused on advancing cancer treatments. As a company with a global reach, its dedicated efforts are towards innovation in the field of oncology, specifically through the creation and development of novel therapies aimed at combating various forms of cancer. With its lead contributions in the biopharmaceutical domain, BeyondSpring Inc. actively engages in substantial clinical and preclinical activities to usher in new eras of cancer therapy.

Products and Services

• Plinabulin for Chemotherapy-Induced Neutropenia:

  As a flagship asset, Plinabulin is a pioneering immune-modulating microtubule-binding agent designed to prevent chemotherapy-induced neutropenia (CIN), a common and severe side effect of cancer treatment. Having completed Phase III clinical trials, this innovation marks a significant stride towards enhancing the quality of life for patients undergoing chemotherapy by mitigating one of its most debilitating side effects.

• Plinabulin for Non-Small Cell Lung Cancer:

  Targeting a broader application in oncology, BeyondSpring has also completed Phase III clinical trials of Plinabulin for the treatment of later-stage non-small cell lung cancer (NSCLC). This effort underscores the company’s commitment to expanding the therapeutic potential of its lead compound, aiming to provide new hope for patients battling this challenging form of cancer.

• Immuno-Oncology Combinations:

  Understanding the complexity of cancer and the necessity for comprehensive treatment approaches, BeyondSpring is engaged in the development of Plinabulin in combination with various immuno-oncology agents. These combinations include nivolumab, a PD-1 antibody for NSCLC; ipilimumab, a CTLA-4 antibody for extensive-stage small cell lung cancer; and collaborations involving PD-1 or PD-L1 antibodies and radiation therapy for diverse cancer indications. Such initiatives reflect the company’s dedication to exploring synergistic treatment modalities that could revolutionize cancer care.

• Preclinical Small Molecule Immune Agents:

  In addition to its clinical endeavors, BeyondSpring is proactively developing three small molecule immune agents at the preclinical stage. These agents represent the frontier of the company’s innovative aspirations, laying the groundwork for future therapeutic interventions that could significantly impact the field of immuno-oncology.

• Drug Development Platform:

  At the core of BeyondSpring’s operations lies its drug development platform, a foundational aspect of its strategic approach to oncology research. This platform enables the systematic discovery, analysis, and development of new drug candidates, ensuring a robust pipeline of innovations aimed at confronting various forms of cancer with groundbreaking therapies.